"This is a significant milestone for our lead oncology COTI-2 program, and potentially for the future of patients afflicted with gynecologic and other cancers. The CTA provides many benefits to our Company, and to the advancement of COTI-2, not the least of which is the caliber of the team that will help to guide this first-in-humans trial. MD Anderson is world-renowned for its state‐of‐the‐art facilities, technical capabilities, and the expertise to successfully execute our Phase 1 clinical trial." - Dr. Wayne Danter.
COTI-2 is a small molecule activator of misfolded mutant p53 protein approved for clinical development. Extensive studies have demonstrated COTI-2's ability to restore mutant p53 function and thus induce cancer cell death in many common p53 mutations. Mutations of the p53 gene are the most common genetic alterations in human cancers, occurring in a wide range of cancers, including ovarian, lung, colorectal, breast, liver, bladder and other cancers. COTI-2's specific protein target, low toxicity, combination effectiveness with standard agents, and potential for longer term outpatient therapy as an oral agent, supports a dramatic change in the treatment of susceptible cancers.
Click here to read our full news release.